Latest Period
Q1 2026
Security Snapshot
Anixa Biosciences Inc - Common Stock (ANIX) Institutional Ownership
CUSIP: 03528H109
13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026
Institutions Reporting
60
Shares (Excl. Options)
5,106,335
Price
$2.58
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- ANIX on Nasdaq
- Shares outstanding
- 35,258,614
- Price per share
- $3.04
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 5,106,335
- Total reported value
- $13,181,046
- % of total 13F portfolios
- 0%
- Share change
- -550,528
- Value change
- -$1,781,879
- Number of holders
- 60
- Price from insider filings
- $3.04
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ANIX - Anixa Biosciences Inc - Common Stock is tracked under CUSIP 03528H109.
- 60 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 70 to 60 between Q4 2025 and Q1 2026.
- Reported value moved from $17,642,741 to $13,181,046.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 60 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 03528H109?
CUSIP 03528H109 identifies ANIX - Anixa Biosciences Inc - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03528H109:
Significant Owners of Anixa Biosciences Inc - Common Stock (ANIX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| KUMAR AMIT | 16% | +8% | $16,667,362 | +$1,403,336 | 6,173,097 | +9.2% | Amit Kumar | 04 Jun 2025 |
| Catelani Michael | 7% | $10,662,205 | 2,468,103 | Michael Catelani | 05 Jan 2026 |
As of 31 Mar 2026, 60 institutional investors reported holding 5,106,335 shares of Anixa Biosciences Inc - Common Stock (ANIX). This represents 14% of the company’s total 35,258,614 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Anixa Biosciences Inc - Common Stock (ANIX) together control 14% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 1,314,982 | 0% | 0% | $3,392,654 |
| Laird Norton Wetherby Trust Company, LLC | 1.6% | 566,327 | -3.7% | 0.03% | $1,461,124 |
| UBS Group AG | 1.6% | 551,637 | +20% | 0% | $1,423,224 |
| D.A. DAVIDSON & CO. | 1.5% | 539,272 | 0% | 0.01% | $1,391,322 |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 364,731 | +3.9% | 0% | $941,440 |
| VANGUARD FIDUCIARY TRUST CO | 0.54% | 191,074 | 0% | 0% | $492,971 |
| MARSHALL WACE, LLP | 0.49% | 173,179 | +327% | 0% | $446,800 |
| BlackRock, Inc. | 0.48% | 170,103 | +3.7% | 0% | $438,865 |
| STATE STREET CORP | 0.45% | 159,040 | 0% | 0% | $410,323 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.28% | 99,468 | -61% | 0% | $256,628 |
| GSA CAPITAL PARTNERS LLP | 0.28% | 98,842 | +20% | 0.02% | $255,000 |
| LPL Financial LLC | 0.23% | 80,976 | -9.6% | 0% | $208,918 |
| NORTHERN TRUST CORP | 0.19% | 66,825 | +20% | 0% | $172,409 |
| RENAISSANCE TECHNOLOGIES LLC | 0.17% | 61,173 | +14% | 0% | $157,826 |
| CoreCap Advisors, LLC | 0.15% | 52,020 | +8.3% | 0% | $134,212 |
| Kestra Advisory Services, LLC | 0.14% | 51,000 | +96% | 0% | $131,580 |
| Bank of New York Mellon Corp | 0.13% | 47,442 | -19% | 0% | $122,401 |
| Westside Investment Management, Inc. | 0.13% | 47,000 | +6.8% | 0.02% | $121,260 |
| HighTower Advisors, LLC | 0.12% | 41,550 | +0.97% | 0% | $107,199 |
| Gemmer Asset Management LLC | 0.1% | 35,000 | 0% | 0.01% | $90,300 |
| Vontobel Holding Ltd. | 0.09% | 30,000 | 0% | $77,400 | |
| CIBC Bancorp USA Inc. | 0.08% | 26,600 | 0% | $68,628 | |
| NATIONS FINANCIAL GROUP INC, /IA/ /ADV | 0.06% | 22,500 | 0% | 0% | $58,050 |
| Corient Private Wealth LLC | 0.06% | 20,000 | -47% | 0% | $51,600 |
| SEGALL BRYANT & HAMILL, LLC | 0.05% | 17,400 | 0% | $51,156 |
Institutional Holders of Anixa Biosciences Inc - Common Stock (ANIX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 5,106,335 | $13,181,046 | -$1,781,879 | $2.58 | 60 |
| 2025 Q4 | 5,655,725 | $17,642,741 | +$715,226 | $3.12 | 70 |
| 2025 Q3 | 5,413,922 | $17,872,434 | +$304,259 | $3.30 | 65 |
| 2025 Q2 | 5,349,047 | $17,648,439 | -$787,212 | $3.30 | 65 |
| 2025 Q1 | 5,605,891 | $16,030,193 | -$524,324 | $2.86 | 57 |
| 2024 Q4 | 5,841,305 | $13,552,284 | +$544,864 | $2.32 | 57 |
| 2024 Q3 | 5,576,916 | $17,555,837 | +$106,953 | $3.15 | 56 |
| 2024 Q2 | 5,565,637 | $12,300,146 | +$344,963 | $2.21 | 52 |
| 2024 Q1 | 5,283,801 | $16,487,763 | +$2,705,766 | $3.12 | 58 |
| 2023 Q4 | 4,420,722 | $17,152,699 | +$1,892,994 | $3.88 | 55 |
| 2023 Q3 | 3,928,249 | $12,844,861 | +$921,910 | $3.27 | 49 |
| 2023 Q2 | 3,647,399 | $11,674,122 | -$399,198 | $3.20 | 45 |
| 2023 Q1 | 3,664,627 | $15,755,697 | +$369,660 | $4.30 | 44 |
| 2022 Q4 | 3,636,173 | $15,451,565 | +$553,415 | $4.25 | 49 |
| 2022 Q3 | 3,474,510 | $17,089,377 | +$1,187,300 | $4.92 | 41 |
| 2022 Q2 | 3,267,227 | $9,991,989 | -$78,782 | $3.06 | 42 |
| 2022 Q1 | 3,302,911 | $9,050,644 | -$407,464 | $2.74 | 37 |
| 2021 Q4 | 3,436,723 | $10,208,000 | +$525,035 | $2.97 | 39 |
| 2021 Q3 | 3,177,493 | $15,156,000 | +$1,098,635 | $4.77 | 34 |
| 2021 Q2 | 2,951,398 | $11,453,000 | -$36,263,645 | $3.88 | 29 |
| 2021 Q1 | 2,512,086 | $49,594,000 | +$41,200,982 | $4.68 | 27 |
| 2020 Q4 | 1,800,328 | $5,527,000 | +$13,066 | $3.07 | 20 |
| 2020 Q3 | 1,825,831 | $4,439,000 | +$532,898 | $2.43 | 19 |
| 2020 Q2 | 1,596,826 | $4,888,000 | +$720,757 | $3.06 | 18 |
| 2020 Q1 | 1,382,434 | $2,197,000 | +$44,107 | $1.59 | 15 |
| 2019 Q4 | 1,327,691 | $4,354,000 | +$51,850 | $3.28 | 14 |
| 2019 Q3 | 1,311,710 | $5,247,000 | +$341,126 | $4.00 | 14 |
| 2019 Q2 | 1,226,425 | $4,448,000 | -$180,456 | $3.63 | 13 |
| 2019 Q1 | 1,251,395 | $5,657,000 | +$702,078 | $4.52 | 14 |
| 2018 Q4 | 1,095,942 | $4,318,000 | +$4,318,000 | $3.94 | 13 |